Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions in Europe.
Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.
Corey Goodman, the managing partner at venBio, is joining a group of VCs backing Ireland's Heart Metabolics, which is positioning a Phase III-ready heart disease drug for the clinic.
A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.
After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.
Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.
The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.
The Nasdaq biotech index is down more than 20 percent since February, which has caused considerable anguish among the gamblers wooed into the high-risk field as stocks boomed last year. But some analysts are betting that the worst is over and that the correction has run its course.